17 results
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
13 Jul 23
HUTCHMED Announces Changes to Board of Directors and Technical Committee
6:03am
will not join the Board.
Taking into account the expertise and reputation of Professor Peters in biopharmaceutical research in oncology and in immunology
CORRESP
HCM
HUTCHMED (China) Limited
8 Jun 22
Correspondence with SEC
12:00am
by customers and other affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our … General. Such notices could harm our reputation and our ability to compete and could potentially attract enforcement scrutiny from governmental
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
21 Jun 21
HUTCHMED (China) Limited Supplemental and Updated Disclosures
6:27am
have a material adverse effect on our reputation, business and results of operations.
RISKS RELATING TO THE GLOBAL OFFERING AND OUR LISTINGS IN HONG … safety, level of technology, qualifications and reputation of the manufacturer, after-sale services and innovation. As a result, the prices of our
6-K
s56dd4
21 Jun 21
HUTCHMED (China) Limited Supplemental and Updated Disclosures
6:27am
6-K
EX-99.1
zbx37 963
11 Jan 21
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
6:07am
6-K
EX-99.1
8zyzn hnojgt
15 Apr 19
Current report (foreign)
7:21am
20-F
du5 5v885
13 Mar 17
Annual report (foreign)
12:00am
F-1
EX-10.24
xqcqid
16 Oct 15
Registration statement (foreign)
12:00am
F-1
4hu1w owhwgm
16 Oct 15
Registration statement (foreign)
12:00am
F-1
EX-10.1
70psxlpm 799f
16 Oct 15
Registration statement (foreign)
12:00am
F-1
EX-99.1
py540irtnw95 7hzhq
16 Oct 15
Registration statement (foreign)
12:00am
- Prev
- 1
- Next